基药目录管理办法时隔11年首次修订

Core Viewpoint - The newly revised "National Essential Medicines Directory Management Measures" emphasizes the importance of clinical value in the selection of essential medicines and establishes a rigid adjustment cycle of no more than three years for the essential medicines directory [3][5][6]. Group 1: Essential Medicines Directory - The essential medicines are defined as those that meet basic healthcare needs, are suitable for the current national conditions, are reasonably priced, and can be fairly accessed [5]. - The previous version of the essential medicines directory had not been updated since 2018, which included 685 varieties of medicines [5]. - The new management measures stress the importance of timely adjustments to the directory, with a principle of regular evaluation and dynamic management [5][6]. Group 2: Clinical Value and Selection Process - The revised management measures highlight the need to prioritize clinical value in the selection of essential medicines, with a focus on including more innovative drugs that meet clinical needs [6][7]. - The selection process for the essential medicines directory does not accept applications from companies; instead, it is determined by a coordination mechanism involving 11 departments [6][7]. Group 3: Coordination with Other Policies - The new management measures aim to improve coordination with other healthcare policies, including medical insurance and centralized procurement [8][11]. - The previous requirement for all grassroots medical institutions to use essential medicines has been removed to allow for more flexibility in drug selection [10]. - Future adjustments to the essential medicines directory will consider various factors, including public health needs, disease spectrum changes, and clinical evaluations [12].